LLY vs PGNY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
PGNY exhibits exceptional fundamental health, highlighted by a perfect Piotroski F-Score of 9/9 and a negligible Debt/Equity ratio of 0.05. While the stock has suffered significant long-term price decay and currently faces bearish technical trends and insider selling, the valuation is highly attractive on a forward basis with a Forward P/E of 8.53. The company's consistent track record of earnings beats and strong earnings growth (20.6% YoY) suggests a disconnect between market sentiment and operational performance. The current price of $17.93 sits comfortably below the growth-based intrinsic value of $19.77 and well below analyst targets.
Compare Another Pair
Related Comparisons
LLY vs PGNY: Head-to-Head Comparison
This page compares Eli Lilly and Company (LLY) and Progyny, Inc. (PGNY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.